- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07740044
Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Chronic Disease Management
27 juillet 2026 mis à jour par: Jiangsu Taizhou People's Hospital
Verification and Application Study of Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Chronic Disease Management: A Randomized Controlled Study
This study aims to explore the feasibility of using medical large language models to assist in chronic disease management.
By setting up experimental and control group interventions and having experts blindly evaluate anonymized cases, it compares different management approaches in chronic disease care, verifying the scientific basis, effectiveness, and potential for broader use of medical large language models in supporting chronic disease management.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
20
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Guoyu Wang, MD
- Numéro de téléphone: +8615951154720
- E-mail: wangguoyutzheart@163.com
Lieux d'étude
-
-
Jiangsu
-
Taizhou, Jiangsu, Chine, 225300
- The Affiliated Taizhou People's Hospital of Nanjing Medical University
-
Contact:
- Guoyu Wang, MD
- Numéro de téléphone: +8615951154720
- E-mail: wangguoyutzheart@163.com
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Work experience of 3 years or more;
- Able to complete the case assessment tasks required by the study;
- Have a practicing doctor qualification;
- Work at a township health center or community health service center;
- Voluntarily participate in the study and sign the informed consent form.
Exclusion Criteria:
N/A
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: LLM-Assisted Intervention Group
Primary care doctors creating management plans for chronic diseases (coronary heart disease, atrial fibrillation, heart failure, stroke) with the help of large medical language models
|
The primary care physicians in the intervention group completed the management decisions for chronic disease cases, including disease assessment, examination suggestions, treatment plans, selection of management methods, and health education, with the assistance of the medical LLM.
|
|
Aucune intervention: Usual Care Control Group
Primary care doctors creating management plans for chronic diseases (coronary heart disease, atrial fibrillation, heart failure, stroke) without the help of a large medical language model
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
expert overall scores
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale on several aspects: accuracy of condition assessment, reasonableness of test recommendations, reasonableness of treatment plans, appropriateness of management choices, scientific nature of patient education content, feasibility at the primary care level, overall clinical quality.
Experts were instructed to rank the seven dimensions from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
accuracy of condition assessment
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale on accuracy of condition assessment from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
reasonableness of test recommendations
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the reasonableness of test recommendations.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
reasonableness of treatment plans
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the reasonableness of treatment plans.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
appropriateness of management choices
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the ppropriateness of management choices.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
scientific nature of patient education content
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the scientific nature of patient education content.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
feasibility at the primary care level
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the feasibility at the primary care level.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
the overall clinical quality
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
They rated them using a Likert scale regarding the overall clinical quality.
Experts were instructed to rank the dimension from lowest to highest quality.
These ordinal rankings were then converted into standardized scores of 1 to 5. Higher scores mean better.
|
through study completion, an average of 3 months.
|
|
risk advice
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
If there is no risk advice, the expert selects 'No'; otherwise, the expert selects 'Yes' and specifically lists the content of the risk advice.
|
through study completion, an average of 3 months.
|
|
Any diagnostic or treatment information missing
Délai: through study completion, an average of 3 months.
|
A total of 200 cases (50 each of coronary heart disease, atrial fibrillation, heart failure, and stroke) were grouped by disease type and independently evaluated in a blinded manner by three subspecialty experts.
For each case, the two management plans were anonymized in the same way and then randomly labeled by a computer as Plan A and Plan B. Experts could only view the anonymized case information and the two corresponding anonymized management plans.
If there is no omission of diagnostic and treatment information, the expert selects "No"; otherwise, the expert selects "Yes" and specifically lists the omitted diagnostic and treatment content.
|
through study completion, an average of 3 months.
|
|
feedback regarding the use of medical LLM by primary care physicians
Délai: through study completion, an average of 3 months.
|
After primary care physicians complete a case assessment assisted by medical LLM , they will fill out an evaluation of the medical LLM usage, including whether the medical LLM helped in disease assessment, assisted in formulating examination plans, aided in developing treatment plans, improved chronic disease management capabilities, supported chronic disease education, assisted in management approach selection, enhanced confidence, saved time, whether there were hallucinations or omissions, whether it provided risky suggestions, and any additional comments on the use of the medical LLM.
|
through study completion, an average of 3 months.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
17 août 2026
Achèvement primaire (Estimé)
30 septembre 2026
Achèvement de l'étude (Estimé)
30 novembre 2026
Dates d'inscription aux études
Première soumission
20 juillet 2026
Première soumission répondant aux critères de contrôle qualité
27 juillet 2026
Première publication (Réel)
31 juillet 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
31 juillet 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
27 juillet 2026
Dernière vérification
1 juillet 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Arythmies cardiaques
- Artériosclérose
- Maladies artérielles occlusives
- Maladie coronarienne
- Ischémie myocardique
- Conditions pathologiques, signes et symptômes
- Accident vasculaire cérébral
- Insuffisance cardiaque
- Fibrillation auriculaire
- Maladie de l'artère coronaire
Autres numéros d'identification d'étude
- LSKY 2026-114-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .